华西口腔医学杂志

• 其他 • 上一篇    

Cochrane系统评价在口腔黏膜病诊治中的应用

李琼华 陈谦明 曾昕   

  1. 四川大学华西口腔医院黏膜科, 四川成都610041
  • 收稿日期:2010-10-25 修回日期:2010-10-25 出版日期:2010-10-20 发布日期:2010-10-20
  • 通讯作者: 陈谦明,Tel:028-85503480
  • 作者简介:李琼华(1984—),女,陕西人,硕士

Application of Cochrane systematic reviews in diagnosis and treatment for oral mucosal diseases

LI Qionghua, CHEN Qian-ming, ZENG Xin   

  1. Dept. of Oral Medicine, West China College of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2010-10-25 Revised:2010-10-25 Online:2010-10-20 Published:2010-10-20
  • Contact: CHEN Qian-ming,Tel:028-85503480

摘要:

目的收集与口腔黏膜病诊治相关的循证医学证据。方法检索Cochrane图书馆已发表的(截至2009年第3期)与口腔黏膜病诊治有关的系统评价的全文,对其结果进行简要介绍,对该领域系统评价证据的现状进行分析。结果治疗口腔黏膜下纤维化的干预措施的可靠证据依然缺乏;在预防癌症患者放疗和化疗后口腔黏膜炎的干预措施中,有证据显示氨磷汀、水解酶、冰片和中药是有效的;而采用别嘌呤醇漱口液、粒细胞巨噬细胞集落刺激因子、免疫球蛋白和人胎盘提取物治疗癌症患者放疗和化疗后口腔黏膜炎的证据仍不充分;阿昔洛韦预防和治疗癌症患者单纯性疱疹的效果是有证据支持的;由胃肠道吸收或部分由胃肠道吸收的药物预防癌症患者放疗和化疗后口腔假丝酵母菌病的疗效明显;应用β胡萝卜素、番茄红素、维生素A或视黄醇类药物治疗口腔白斑的不良反应较常见;治疗口腔扁平苔藓的措施,如环孢菌素、视黄醇类、皮质类固醇以及光疗法等,其疗效尚无肯定结论;阿昔洛韦治疗原发性疱疹性龈口炎的证据有限;有关治疗灼口综合征的干预措施的证据较少。结论通过提高科研设计和实施的质量,才能为系统评价提供坚实的证据,从而提高口腔黏膜病的循证治疗水平。

关键词: 口腔黏膜病, Cochrane系统评价, 临床证据

Abstract:

Objective To collect evidence in diagnosis and treatment of oral mucosal diseases. Methods The Cochrane library(Issue 3, 2009) was searched to get the full texts of published related Cochrane systematic reviews. The results were summarized for recommendation to dentists. The current status of evidence based medicine in this field was analyzed. Results Reliable evidence for management of oral submucous fibrosis is still limited; amifostine, hydrolytic enzymes, ice chips and Chinese medicine may be effective in preventing oral mucositis for patients with cancer receiving radiotherapy or chemotherapy; the evidence in treating oral mucositis with allopurinol mouthwash, granulocyte macrophage-colony stimulating factor, immunoglobulin or human placentral extract for patients with cancer receiving treatment is weak and unreliable yet; there is evidence that acyclovir is efficacious in prevention and treatment of herpes simplex virus infections in patients being treated for cancer; there is strong evidence that drugs absorbed or partially absorbed from the gastrointestinal tract prevent oral candidiasis in patients receiving treatment for cancer; relapses and adverse effects are common in using beta carotene, lycopene, vitamin A or retinoids to treat oral leukoplakia; only some weak evidence is provided in using cyclosporines, retinoids, steroids or phototherapy for treating oral lichen planus; the evidence about acyclovir for treating primary herpetic gingivostomatitis is insufficient; there is little research evidence for treatment of burning mouth syndrome. Conclusion It is essential to raise the quality of design and conduction of clinical trials in the field of oral mucosal disease to provide solid bases for systematic review, so that to improve evidence based treatment of these diseases.

Key words: oral mucosal disease, Cochrane systematic review, clinical evidence